Yield of combined impedance-pH monitoring for refractory reflux symptoms in clinical practice

Journal of Neurogastroenterology and Motility

Volumn 17, Issue 2, 2011, Pages 158-163

  Karamanolis, Georgios ^a   Kotsalidis, Georgios ^a   Triantafyllou, Konstantinos ^a   Polymeros, Dimitrios ^a   Gaglia, Asimina ^a   Fessatou, Smaragdi ^a   Triantafyllou, Maria ^a   Papanikolaou, Ioannis ^a   Ladas, Spiros D ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

Electric impedance; Esophageal pH monitoring; Gastroesophageal reflux

Indexed keywords

EID: 80054950374     PISSN: 20930879     EISSN: 20930887     Source Type: Journal    
DOI: 10.5056/jnm.2011.17.2.158     Document Type: Article

References (25)

1. Isolauri J, Laippala P. Prevalence of symptoms suggestive of gastroesophageal reflux disease in an adult population. Ann Med 1995; 27:67-70.
2. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976; 21:953-956.
3. Kahrilas PJ, Shaheen NJ, Vaezi MF; American Gastroenterological Association Institute; Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008;135:1392-1413.
4. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95:903-912.
5. Sontag SJ, Hirschowitz BI, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: The U.S. Multicenter Study. Gastroenterology 1992;102:109-118.
6. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994;121:161-167.
7. Leite LP, Johnston BT, Just RJ, Castell DO. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 1996;91:1527-1531.
8. Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004;2:656-664.
9. Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. Simultaneous intraesophageal impedance and pH measurement of acid and non-acid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001;120:1599-1606.
10. Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastroesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004;53:1024-1031.
11. Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006;55:1398-1402.
12. Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom association analysis in patients off and on therapy. Am J Gastroenterol 2006;101:1956-1963.
13. DeVault KR, Castell DO; American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190-200.
14. Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005;100:283-289
15. Karamanolis G, Vanuytsel T, Sifrim D, et al. Yield of 24-hour esophageal pH and Bilitec monitoring in patients with persistent symptoms on PPI therapy. Dig Dis Sci 2008;53:2387-2393.
16. Bredenoord AJ, Weusten BL, Timmer R, Smout AJ. Minimum sample frequency for multichannel intraluminal impedance measurement for the oesophagus. Neurogastroenterol Motil 2004;16:713-719.
17. Lam HG, Breumelhof R, Roelofs JM, Van Berge Henegouwen GP, Smout AJ. What is the optimal time window in symptom analysis of 24-hour esophageal pressure and pH data? Dig Dis Sci 1994;39: 402-409.
18. Bredenoord AJ, Weusten BL, Smout AJ. Symptom association analysis in ambulatory gastro-oesophageal reflux monitoring. Gut 2005;54:1810-1817.
19. Sharma N, Agrawal A, Freeman J, Vela MF, Castell D. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol 2008;6:521-524.
20. Savarino E, Zentilin P, Tutuian R, et al. The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol 2008;103:2685-2693.
21. Blonski W, Vela MF, Castell DO. Comparison of reflux frequency during prolonged multichannel intraluminal impedance and pH monitoring on and off acid suppression therapy. J Clin Gastroenterol 2009;43:816-820.
22. Kline MM, Ewing M, Simpson N, Laine L. The utility of intraluminal impedance in patients with gastroesophageal reflux disease-like symptoms but normal endoscopy and 24-hour pH testing. Clin Gastroenterol Hepatol 2008;6:880-885.
23. Joniau S, Bradshaw A, Esterman A, Carney AS. Reflux laryngitis: a systematic review. Otolaryngol Head Neck Surg 2007;136:686-692.
24. Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001;15:1351-1356.
25. Becker V, Bajbouj M, Waller K, Schmid RM, Meining A. Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors - a follow-up study of intraluminal-impedance guided therapy. Aliment Pharmacol Ther 2007; 26:1355-1360.